Purpose: Recently, we established an ELISA technique for measuring nm23-H1 protein in serum and found that the serum nm23-H1 level is a potential prognostic factor for patients with non-Hodgkin's lymphoma.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 35-40% of non-Hodgkin's lymphomas. Short-term cyclophosphamide-doxorubicin-vincristine-prednisolone chemotherapy coupled with localized radiotherapy and cyclophosphamide-doxorubicin-vincristine-prednisolone chemotherapy are considered standard treatment modalities for patients with localized disease and for those with advanced disease, respectively (1). The treatment for DLBCL has undergone a remarkable change because of the development of anti-CD20 monoclonal antibody, as used in rituximab therapy (2) , and chemotherapy combined with rituximab may be in the mainstream of DLBCL treatment in the near future. It is important to predict the prognosis before initiating a selected treatment, such as high-dose chemotherapy combined with peripheral blood stem cell transplantation after rituximab-combined chemotherapy. International Prognostic Index (IPI) is generally used for this purpose (3), because it can distinguish low-risk patients, to whom standard treatments can be applied, from high-risk patients, for whom such treatments may not be very effective. In addition, the IPI is based on simplified clinical characteristics, thereby allowing the collection of data from all patients before treatment. Thus, by using the IPI, it has become possible to predict a fairly accurate prognosis and, based on that prognosis, to make a stratified treatment plan appropriate for each patient.
Recently, DLBCL was categorized into two groups according to the pattern of gene expression. Prognosis was poorer in a group of patients with activated-B-cell-like (ABC) DLBCL than that with germinal-center-B-like (GCB) DLBCL, and this classification had a prognostic value even within a group of IPIlow-risk patients (4) . It is speculated that prognostication of patients with lymphoma would be based on such molecular characterization of neoplastic cells in the future, but it has, thus far, been difficult to obtain the data of gene expression before starting treatment. Also, because of aspects of cost and sample collection, it will take more time for such molecular characterization to be part of a routine pretreatment examination.
Previously, we established an ELISA technique to determine the serum level of nm23-H1 protein (5) . Originally, nm23-H1 was identified as a protein that was expressed at a lower level in metastatic cancer cells (6) . Since then, low expression or mutation of nm23-H1 and nm23-H2 has been implicated in cancer prognosis or metastasis in a variety of tumors and malignant transformations. nm23 genes play critical roles in cellular proliferation, differentiation, oncogenesis, and tumor metastasis (7, 8) . The mechanisms responsible for these Fig. 1 nm23-H1 immunostaining. In a reactive lymph node, centroblasts in the germinal centers, transformed lymphocytes in the interfollicular areas, and plasma cells in the medullary cords were positively stained (A). At a higher magnification, weak cytoplasmic staining was also seen in sinus histiocytes and endothelial cells (B). The neoplastic cells of Hodgkin's lymphoma (C), follicular lymphoma (D), mantle-cell lymphoma (E), and diffuse large B-cell lymphoma (F) showed cytoplasmic staining. Immunoperoxidase stain with hematoxylin counterstain. A, ϫ10; B and F, ϫ50; C, ϫ100; D and E, ϫ25.
pleiomorphic effects are not well understood. We previously reported that serum levels of nm23-H1 in aggressive nonHodgkin's lymphomas and acute myelogenous leukemia were significantly higher than those in controls, and that high nm23-H1 levels correlated with poor prognosis in both aggressive non-Hodgkin's lymphomas and acute myelogenous leukemia (5, 6) . In a multi-institutional study involving a large number of patients, we found that serum nm23-H1 was an important and independent prognostic factor for patients with DLBCL and with peripheral T-cell lymphoma (9) . Although there were still several unknowns, including the question of whether serum nm23-H1 is produced by lymphoma cells directly, and whether there is a correlation between serum nm23-H1 and intracellular nm23-H1 expression by the tumor cells, our subsequent studies (10, 11) indicated that these factors are possible. In the present study, we, therefore, evaluated intracellular nm23-H1 protein expression using immunohistochemistry.
PATIENTS AND METHODS
Patients. We collected consecutive and untreated patients with B-cell lymphoma (n ϭ 244) and Hodgkin's lymphoma (HL; n ϭ 18), who were managed by the Adult Lymphoma Treatment Study Group in Japan from 1997 to 2002. Twelve patients in our previous report on the serum nm23-H1 levels (9) were included in the present study. The lymphomas were classified according to the WHO classification as defined elsewhere (12) . Of the 244 patients with B-cell neoplasms, 15 had mucosaassociated lymphoid tissue (MALT) lymphoma, 18 had mantel cell lymphoma (MCL), 4 had B-cell chronic lymphocytic leukemia (CLL), 29 had follicular lymphoma (FL; including 3 with grade 1, 14 with grade 2, and 12 with grade 3), 172 had DLBCL, and 6 had lymphoblastic lymphoma (LBL). Of the 18 patients with HL, 8 had mixed cellularity HL and 10 had nodular sclerosis HL. The median age of the patients was 64 years (range, 18 -90 years). Clinical staging was performed according to the Ann Arbor classification system (13 treated with a single agent or a combination of cyclophosphamide, vincristine, and prednisone (COP). Patients were followed at intervals of several months. Re-evaluation of clinical records included physical findings, complete blood counts, biochemistry data, and computed tomograms of the chest, abdominal, and pelvic areas. The median follow-up time was 34 months (range, 8 to 62 months). All of the patients gave informed consent for both treatment and sample collection in accordance with institutional policy.
Immunohistochemical Staining. The expression of nm23 by lymphoma cells was examined immunohistochemically on formalin-fixed, paraffin-embedded sections by the avidin-biotin-peroxidase complex method. Two monoclonal antibodies to nm23-H1 [clone 37.6 (Novocastra Laboratories, Ltd, Newcastle upon Tyne, United Kingdom); clone H1-229 (Seikagaku Corporation, Tokyo, Japan)] and a monoclonal antibody to nm23-H2 (clone H2-206; Seikagaku Corporation) were used as primary reagents. Working dilutions of these antibodies and tissue distribution of positive cells were checked by using lymph nodes with reactive hyperplasia. Consequently, clone 37.6 among the above antibodies gave satisfactory staining at a range of 1:50 to 1:200 dilutions. Weak cytoplasmic staining was also seen in sinus histiocytes and endothelial cells. Because the two antibodies (clone H1-229 and clone H2-206) showed faint staining even at a 1:50 dilution by our method, clone 37.6 was used as the antihuman nm23 antibody for the study, and it was used at a 1:100 dilution. A given lymphoma cell that showed distinct immunostaining was judged to be positive for nm23-H1. The nm23-H1 expression was analyzed semiquantitatively according to the proportion of positively stained lymphoma cells. Two hundred lymphoma cells were analyzed. The degree of nm23-H1 positivity was categorized as "weak/none" if 30% or less of the lymphoma cells were positively stained; "moderate" if the proportion of the positively stained cells were in a range between 31 and 70%; or "strong" if more than 70% of the cells were positively stained (16) . For univariate and multivariate analyses, staining of 31% or more of the tumor cells was defined as positive, and staining of 30% or less of the tumor cells was defined as negative.
ELISA for Human nm23-H1. We previously established an ELISA procedure to determine nm23-H1 protein levels in the serum (5). Briefly, 96-well plates (Corning Co., Corning, NY) were coated with a monoclonal anti-nm23-H1 antibody (Seikagakukougyo Co., Tokyo, Japan), washed four times with PBS, and incubated with 25% Block Ace solution (Dainihon Seiyaku, Osaka, Japan). Serum samples were diluted 2-fold with PBS, and 50-l aliquots were added to the wells. After incubation at room temperature for 1 h, the wells were washed four times with PBS containing 0.05% Tween 20 (T-PBS). Samples were then incubated at room temperature for 1 h with a polyclonal rabbit anti-nm23-H1 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA), washed four times with T-PBS, and incubated with alkaline phosphatase-conjugated antirabbit IgG (Bio-Rad Lab, Richmond, CA). After four washes with T-PBS, alkaline phosphatase activity was detected with diethanolamine as a substrate and an alkaline phosphatasedetecting kit (Bio-Rad Lab). The reaction was stopped with 50 l of 0.4 N NaOH. Absorbance was measured at 405-415 nm with a correction wavelength of 620 -630 nm using a microplate reader.
Statistical Analyses. The patients' characteristics were compared using 2 tests. Complete remission was defined as the absence of detectable disease based on clinical, radiological, and histological criteria. Judgment criteria used for the analysis were overall survival (OS) and progression-free survival (PFS). Progression was defined as either a progression of the lymphoma in nonresponding patients or partial response patients, a relapse for complete response patients, or death from any cause without progression. PFS was calculated as the duration from randomization to the date of the first progression. Patients who did not experience a progression at the time of analysis were censored at the most recent date of disease assessment or at the stop date if the most recent date was later. OS was measured from the date of randomization to the date of death, regardless of cause of the death. Patients who were still living at the time of analysis were censored at the most recent date of disease assessment or at the stop date if the most recent date was later. Survival analysis was performed according to the Kaplan-Meier method (17) . The statistical significance of the differences in survival was determined by the log-rank and generalized Wilcoxon's tests (18) . Differences between groups were evaluated by the MannWhitney U test (nonparametric analysis; Ref. 19) , and P Ͻ 0.05 was taken to indicate significance. Multivariate analysis of the prognosis was performed using Cox's proportional-hazards regression model (20) . All of the statistical analyses were performed with SAS software (version 6.10, SAS Institute, Cary, NC).
RESULTS
Studies of Cytoplasmic nm23-H1 Protein Expression in Each Histopathological Type. As has been reported (21), the reaction products for nm23-H1 were found primarily in the cytoplasm of centroblasts in the germinal centers, transformed lymphocytes in the interfollicular areas, and plasma cells in the medullary cords of a lymph node with reactive hyperplasia (Fig.  1A) . Weak cytoplasmic staining was also seen in sinus histiocytes and endothelial cells (Fig. 1B) . Positively stained examples of HL, FL, MCL, and DLBCL are shown in Fig. 1, C-F . The staining was primarily cytoplasmic in these lymphoma cells. Of the 262 B-cell lymphoma and HL, 150 (57.3%) were strongly positive for nm23-H1 (Table 1 ). According to histopathological type, 75% of HL (mixed cellularity), 90% of HL (nodular sclerosis), 33.3% of MALT, 66.7% of MCL, 25% of CLL, 41.4% of FL (none of grade 1, 35.7% of grade 2, 58.3% of grade 3), 58.1% of DLBCL, and none of LBL were nm23-H1-strongly positive. The strongly positive rate of nm23-H1 was higher in HL, MCL, and DLBCL, and lower in MALT, CLL, and LBL. However, there was no statistically significant difference. The strongly positive rate of nm23-H1 was significantly higher in HL than in LBL (P ϭ 0.035). In FL, the rate of nm23-H1 expression increased as the histological grade increased from 1 to 3, but the difference was not statistically significant. Moderately positive staining (i.e., positive staining in 31-70% of lymphoma cells) was observed in 40 (16.8%) of the 238 mature B-cell neoplasms and in 36 (20.9%) of the 172 DLBCLs.
The 172 patients with DLBCL were investigated further. Fig. 2 Relationship between the serum nm23-H1 level and cytoplasmic nm23-H1 expression in patients with diffuse large-cell lymphoma. (Table 2) . Fifty-five (60.4%) of 91 patients with nodal lymphoma and 45 (55.6%) of 81 patients with extranodal lymphoma were nm23-H1-strongly positive, but there was no statistically significant difference between these groups. Seventeen (81%) of 21 patients with primary tonsillar lymphoma and 28 (46.7%) of 60 patients with extranodal lymphomas other than tonsillar lymphoma were nm23-H1-strongly positive. The nm23-H1-strongly positive rate was significantly higher in primary tonsillar lymphoma than in primary nodal lymphoma (P ϭ 0.03) and in extranodal lymphoma other than tonsil (P ϭ 0.003).
Relationship between nm23-H1 Expression and Clinical Characteristics in DLBCL.
The relationship between nm23-H1 expression and clinicopathological factors was investigated in 172 patients with DLBCL (Table 3) . nm23-H1 expression was significantly correlated with poor performance status (P ϭ 0.025), advanced stage (P ϭ 0.023), presence of bulky mass (P ϭ 0.015), presence of B symptoms (P ϭ 0.0045), elevated serum level of soluble interleukin-2 receptor (P ϭ 0.011), and elevated serum level of C-reactive protein (P ϭ 0.023). There was no significant correlation between nm23-H1 expression and age, serum lactate dehydrogenase level, or IPI. The nm23-H1-positive rate in patients who achieved complete remission was 52.7%, whereas in those who failed to do so, it was 95.5%, and the difference was statistically significant (P ϭ 0.00069). Thus, a close relationship between cytoplasmic nm23-H1 expression and therapeutic responsiveness was found.
Comparison between Serum nm23-H1 Levels and Cytoplasmic nm23-H1 Expression in DLBCL. The serum nm23-H1 level in 100 patients with cytoplasmic nm23-H1-strongly positive DLBCL was 45.86 Ϯ 29.45 ng/ml (mean Ϯ SD), that with cytoplasmic nm23-H1-moderately positive DL-BCL was 36.32 Ϯ 25.11 ng/ml, and that with cytoplasmic nm23-H1-weakly positive/negative DLBCL was 27.86 Ϯ 21.93 ng/ml. Although there was no significant difference in the serum nm23-H1 level between the patients with weakly positive/negative staining and those with moderately positive staining (P ϭ 0.064), there were significant differences between the patients with strongly positive staining and those with moderately positive staining (P ϭ 0.031) and also between those with strongly positive staining and those with weakly positive/negative staining (P ϭ 0.00012; Fig. 2 ). Because the number of nm23-positive lymphoma cells and the serum nm23-H1 level were correlated, it is suggested that a portion of the serum nm23-H1 molecules were derived directly from lymphoma cells.
Correlation of nm23-H1 Expression with OS and PFS in DLBCL.
In all 172 DLBCL patients, the 4-year OS and PFS rates were 62.3 and 59.7%, respectively. The patients were divided into three groups according to the level of cellular nm23-H1 expression. The 4-year OS rates of the patients with weakly positive/negative (n ϭ 36), moderately positive (n ϭ 36), and strongly positive (n ϭ 100) nm23-H1 immunostaining were 92.5, 77.8, and 46.1%, respectively, and there was a correlation among the three groups by the log-rank test (P ϭ 0.00012) and the generalized Wilcoxon's test (P ϭ 0.00061). Both tests revealed significant differences in the 4-year OS between the patients with weakly positive/negative and those with moderately positive staining (P ϭ 0.0035 and P ϭ 0.0046, respectively), between those with moderately positive and those with strongly positive staining (P Ͻ 0.0001 and P Ͻ 0.0001, respectively), and between those with strongly positive staining and those with weakly positive/negative staining (P Ͻ 0.0001 and P Ͻ 0.0001, respectively). PFS was examined in a similar manner. The 4-year PFS rates among patients with weakly positive/negative, moderately positive, and strongly positive staining were 92.4, 50.3, and 35.5%, respectively. The log-rank test and generalized Wilcoxon's test revealed a statistical correlation among the three groups (P ϭ 0.00032 and P ϭ 0.00034, respectively). Both tests revealed significant differences in the 4-year PFS between those with weakly positive/negative and those with moderately positive staining (P ϭ 0.00032 and P ϭ 0.00028, respectively), and between those with moderately positive and those with strongly positive staining (P ϭ 0.039 and P ϭ 0.0132). For evaluation of possible prognostic value of serum nm23-H1, we tried to set the various cutoff points at Ͼ14.39 ng/ml, which was the upper limit in control sera (6.13 ϩ 2SD). The cutoff points used here were 14.39 ng/ml (Ͻ14.39, n ϭ 29 versus Ն14.39, n ϭ 143), 25 ng/ml (median; Ͻ25, n ϭ 83 versus Ն25, n ϭ 89), 80 ng/ml (Ͻ80, n ϭ 143 versus Ն80, n ϭ 29), and 100 ng/ml (Ͻ100, n ϭ 168 versus Ն100, n ϭ 4). All of the cutoff values showed significant prognostic effects (data not shown). The 3-year OS rate of the patients with serum nm23-H1 levels greater than 80 ng/ml (n ϭ 29) was 17.4%, whereas the rate of those with the levels less than 80 ng/ml (n ϭ 143) was 76.9% (log-rank test, P Ͻ 0.0001; generalized Wilcoxon's test, P Ͻ 0.0001; Fig. 4A ). Analysis of the 3-year PFS showed similar results (Fig. 4B) . The 4-year OS and PFS were also analyzed by setting the cutoff value of serum nm23-H1 at 25 ng/ml, and the same results were obtained (Fig. 4, C and D) . Therefore, as in the previous studies, it was confirmed that the patients with high serum nm23-H1 levels had a significantly poorer prognosis.
Univariate and Multivariate Analyses of OS and PFS in Patients with DLBCL.
In patients with DLBCL, the OS was significantly worse for patients with the following characteristics: age of 60 years or older, WHO performance status of 2-4, Ann Arbor stage III/IV, more than one extranodal site, a member of the IPI H-I ϩ H risk groups, bulky disease, B symptoms, soluble interleukin-2 receptor level of 1000 units/ml or higher, nm23-H1 level of 80 ng/ml or higher, and positive cytoplasmic nm23-H1 expression by the lymphoma cells. The PFS rate was significantly lower in patients with the following characteristics: age of 60 years or older, performance status of 2-4, normal or elevated serum lactate dehydrogenase levels, Ann Arbor stage III/IV, more than one extranodal site, a member of the IPI H-I ϩ H risk groups, bulky disease, B symptoms, soluble interleukin-2 receptor level of 1000 units/ml or higher, nm23-H1 level of 80 ng/ml or higher, and cytoplasmic nm23-H1 expression by the lymphoma cells (Table 4) . A multivariate analysis revealed that the five prognostic factors used to calculate the IPI score and the cytoplasmic nm23-H1 expression were associated with OS and PFS. These results indicate that the nm23-H1 expression is an independent prognostic factor that may predict both OS and PFS (data not shown). Also, when serum nm23-H1 level was added to the above-mentioned six factors, both the cytoplasmic nm23-H1 expression and serum nm23-H1 level were independent prognostic factors ( Table 5) . When OS was evaluated by a stepwise method, the serum nm23-H1 level was significant at P ϭ 0.0001, with the relative risk of death of 5.89, and a 95% confidence interval from 3.34 to 10.39, and the cytoplasmic nm23-H1 expression was significant at P ϭ 0.0001, with the relative risk of death of 5.35, and a 95% confidence interval from 2.51 to 11.38. This was also true for ascertaining PFS in patients with DLBCL.
DISCUSSION
In this study, we evaluated intracellular nm23-H1 protein expression by immunohistochemistry to examine whether serum nm23-H1 is derived directly from lymphoma cells. First, we evaluated cytoplasmic nm23-H1 by immunohistochemical staining according to the histological types. The positive rate of nm23-H1 was high in HL, DLBCL, FL grade 3, and MCL, and low in MALT, CLL, and LL. In our previous study, serum nm23-H1 levels were significantly higher in HL, FL, and DL-BCL compared with the normal controls, but there was no significant difference in CLL, MALT, MCL, and LBL (9) . Thus, there is a tendency to find many cytoplasmic nm23-H1-positive patients among patients with high serum nm23-H1 levels except for patients with MCL. Then, we evaluated both cytoplasmic and serum nm23-H1 levels in patients with DLBCL. Because the patients positive for cytoplasmic nm23-H1 showed significantly high levels of serum nm23-H1, it is suggested that at least some part of the serum nm23-H1 is derived from lymphoma cells. Next, we evaluated the relationship between treatment efficacy and the positive rate of cytoplasmic nm23-H1 expression in DLBCL. As had already been observed in the cases of serum and cell surface nm23 levels, patients who failed to achieve complete remission displayed a significantly higher positive rate of cytoplasmic nm23-H1. It is suggested by these findings that there is a relationship between nm23-H1 expression and drug resistance.
Recently, therapeutic effects for DLBCL have been improved, at least partly because the choices of treatment have broadened to include high-dose chemotherapy combined with peripheral blood stem cell transplantation, allogeneic bone marrow transplantation, mini-transplantation, and antibody treatment with rituximab or ibritumomab. However, it is important to predict prognosis and make a stratified treatment plan that attains a long remission period with the initial treatment. In other words, it is important to choose a treatment that is adequate without causing secondary cancers, infertility, or organ failure such as cardiopulmonary toxicity in the long survivors, and to choose chemotherapy combined with a molecular targeting drug. The treatment strategy for DLBCL at present is determined generally by the stage and IPI. By using IPI, a fairly accurate prognostication could be made, and, hence, it would be possible to make a stratified treatment plan for each patient. However, IPI is a marker based primarily on clinical findings. In this study, a group of patients with cytoplasmic nm23-H1-positive DLBCL had significantly shorter OS and PFS than did the nm23-H1-negative group. Multivariate analysis also suggested that cytoplasmic nm23-H1, like serum nm23-H1, may be a significant prognostic factor for DLBCL. However, multivariate analysis indicated that there was a higher relative risk associated with elevated serum nm23-H1 than with positive cytoplasmic nm23-H1, suggesting that serum nm23-H1 may be a more useful prognostic factor. In the study of acute myelogenous leukemia (6), serum nm23-H1 levels were correlated with intracellular nm23 mRNA level and the WBC counts, but not with the mRNA level alone. In the background of this correlation, there seems to be a participation of other biological factors, such as cell proliferation and escape from apoptosis. In lymphoma, a portion of serum nm23 appears to reflect the nm23 expression level of each lymph node or lymphoid tissue, because the serum nm23 level shows a correlation with cytoplasmic nm23 or cell surface nm23. It is suggested by its correlation with advanced stage disease and presence of a bulky mass that cytoplasmic nm23 expression is associated with tumor burden. Furthermore, cytoplasmic nm23 expression or the resultant serum nm23 may stimulate certain substances that cause fever and worsen the general condition of the patients, because cytoplasmic nm23 expression was correlated with poor performance status and presence of B symptoms. It may be associated with treatment resistance and escape from apoptosis, because it is correlated with treatment responsiveness and prognosis.
It is generally considered that nm23-H1 is present in the nucleus (about 15%), in the cytoplasm (about 65%), and in the cell membrane (about 20%), and the cytoplasmic nm23-H1 expression was immunohistochemically examined in the present study. Our results suggest that some parts of the serum nm23-H1 molecules were derived from the cytoplasm and the cell membrane of lymphoma cells by secretion and cleavage, and that other parts of it were derived from the background immune cells, such as T cells and/or natural killer cells. Therefore, it can be expected that the serum nm23-H1 level is still higher in lymphoma patients than in normal volunteers even if the patients' lymphomas are immunohistochemically negative for cytoplasmic nm23. In summary, serum nm23-H1 is a rather stable protein that is easily and rapidly measurable using only a small serum volume before initiating treatment. Cytoplasmic nm23-H1 can be more easily examined at the time of conventional phenotypic examinations for diagnosis of lymphoma, but quantitative evaluation of immunohistochemical staining is difficult. Thus, the methods to examine serum nm23-H1 levels and cytoplasmic nm23-H1 expression have their own merits and demerits. In the future, we hope that more useful prognostic factors can be defined by studying more cases. It is also important to study nm23-H1 in lymphomas for further analysis of its functions, because there are still many questions with regard to the functions of nm23-H1.
